Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 6 Neoplasm Metastasis 4 Carcinoma 4 Breast Neoplasms 4 Neoplasms 3 Melanoma 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Glioma 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Unspecified Childhood Solid Tumor, Protocol Specific 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Sarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Ras-mutated Metastatic Colorectal Cancer 1 Prostatic Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neuroectodermal Tumors, Primitive 1 Medulloblastoma 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Glioblastoma 1 Fibrosarcoma 1 Diffuse Intrinsic Pontine Glioma 1

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Anal Cancer Metastatic × reolysin × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡